CD28 and non-small cell lung carcinoma: Meanwhile, the immunosuppressive function of LAMP3+ DCs has been validated in hepatocellular carcinoma (HCC) and non-small-cell-lung cancer (NSCLC) where LAMP3+ DCs showed strong interaction with exhausted T cells, Tregs and proliferating T cells via CD28/B7 binding and IL-15 signaling (104, 105).